Search
Flavin mononucleotide
go.drugbank.com/drugs/DB03247ApprovedInvestigational[L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on … [A274616,L54226] FMN is composed of an isoalloxazine ring - which serves as the active redox center - attached to a ribityl phosphate chain.
Mixtures: Alsimine W Vitamins A D, Tonicol Et A-D-C Ampoules/comprimesLunsotogene parvec
go.drugbank.com/drugs/DB18278ApprovedInvestigational[L56135,L56136] This landmark decision followed designations as a Regenerative Medicine Advanced Therapy (RMAT) and Fast Track, marking the first-ever gene therapy approved to restore a neurosensory function … Lunsotogene parvec is a first-in-class dual adeno-associated virus serotype 1 vector-based gene therapy developed to address an unmet medical need for OTOF-related sensorineural hearing loss.
Synonyms: DB-OTOTechnetium Tc-99m pertechnetate
go.drugbank.com/drugs/DB09314ApprovedInvestigationalPertechnetate has a wide variety of uses within nuclear medicine as it distributes within the body to a similar extent as iodine. … Technetium Tc-99m pertechnetate is a radiopharmaceutical diagnostic agent composed of an oxoanion with the chemical formula TcO4-.
Mixtures: GENERADOR DE SOLUCION INYECTABLE DE PERTECNETATO (99MTC) DE SODIO. 2-50GBQ, TECHNELITE® GENERADOR DE TECNECIO TC 99MCategories: Compounds used in a research, industrial, or household settingQuizartinib
go.drugbank.com/drugs/DB12874ApprovedInvestigationalmaintenance monotherapy resulted in a 22% reduction in the risk of death. … Quizartinib is an oral and potent fms-like tyrosine kinase 3 (FLT3) inhibitor and it is the first drug developed specifically targeting FLT3, as other agents with FLT3 inhibition activities were investigated
Belantamab mafodotin
go.drugbank.com/drugs/DB15719ApprovedInvestigationalWithdrawn[L53673] Later that year in October of 2025, belantamab was granded full approval by the FDA for the a similar indication to the Health Canada one. [L54331] … Belantamab mafodotin, or GSK2857916, is an afucosylated monoclonal antibody that targets B cell maturation antigen conjugated to the microtubule disrupter monomethyl auristatin-F (MMAF).
Ferric cation
go.drugbank.com/drugs/DB13949ApprovedWithdrawnIron is a transition metal with a symbol Fe and atomic number 26. By mass, it is the most common element on Earth. … Resulting from inadequate supply of iron to cells due to depletion of stores, iron deficiency is the most common nutritional deficiency worldwide, particularly affecting children, women of childbearing
Glasdegib
go.drugbank.com/drugs/DB11978ApprovedInvestigationalGlasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … Currently, the current gold standard of AML in older patients is still venetoclax with hypomethylation agents, new clinical combinations of glasdegib are being tested in hope of replacing venetoclax due
Eldecalcitol
go.drugbank.com/drugs/DB05295InvestigationalEldecalcitol (ED-71), a vitamin D analog, is a more potent inhibitor of bone resorption than alfacalcidol in an estrogen-deficient rat model of osteoporosis. … Eldecalcitol, effectively and safely increased lumbar and hip bone mineral density (BMD) in osteoporotic patients who also received vitamin D3 supplementation.
Categories: Vitamin D and AnaloguesDinoprost tromethamine
go.drugbank.com/drugs/DB01160ApprovedVet approvedWithdrawnThe tromethamine (THAM) salt of the naturally occurring prostaglandin F2 alpha, dinoprost tromethamine occurs as a white to off-white, very hygroscopic, crystalline powder. … Dinoprost tromethamine may also be known as dinoprost trometamol, PGF2 alpha THAM, or prostaglandin F2 alpha tromethamine.
Potassium cation
go.drugbank.com/drugs/DB01345ApprovedThe cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge. … The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential.